ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. Stock
ProQR Therapeutics N.V. dominated the market today, gaining €0.13 (6.810%).
With 10 Buy predictions and not the single Sell prediction the community is currently very high on ProQR Therapeutics N.V..
Based on the current price of 1.96 € the target price of 5 € shows a potential of 154.97% for ProQR Therapeutics N.V. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the ProQR Therapeutics N.V. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Company culture" there were negative voices in the community.
Pros and Cons of ProQR Therapeutics N.V. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ProQR Therapeutics N.V. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ProQR Therapeutics N.V. | 6.810% | 13.091% | 9.370% | -36.864% | -24.110% | 41.896% | -43.971% |
| Pharming Group | 1.150% | 6.104% | 2.187% | 74.854% | 61.797% | 34.563% | 27.887% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
Comments
ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat
ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $8.00 price target on the stock.
Show more
Ratings data for PRQR provided by MarketBeat